Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:23:28 EDT Mon 24 Mar 2025
Enter Symbol
or Name
USA
CA



Q:REGN - REGENERON PHARMACEUTICALS INC - https://www.regeneron.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
REGN - Q0.1660.00·662.100.3658.48-4.14-0.61,869.31,228,11324,068658.00  661.00  651.061,211.1999  642.0019:53:06Mar 1115 min RT 2¢

Recent Trades - Last 10 of 24068
Time ETExPriceChangeVolume
19:53:06Q661.00-1.623
19:51:58Q661.00-1.623
19:30:51Q661.00-1.621
19:23:53Q660.21-2.4150
19:20:00Q660.00-2.6220
19:10:51Q661.00-1.628
19:01:43Q660.21-2.411
18:59:14Q660.21-2.41100
18:57:10Q660.21-2.414
18:33:21Q660.00-2.622

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-11 22:50U:REGNNews ReleaseRegeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
2025-03-11 21:32U:REGNNews ReleaseRegeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
2025-03-08 13:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
2025-02-28 07:00U:REGNNews ReleaseLinvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
2025-02-26 07:00U:REGNNews ReleaseOdronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
2025-02-24 15:00U:REGNNews ReleaseLatest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
2025-02-18 00:59U:REGNNews ReleaseDupixent(TM) (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
2025-02-11 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations
2025-02-11 07:01U:REGNNews ReleaseLinvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
2025-02-08 17:40U:REGNNews ReleaseEYLEA HD(TM) (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
2025-02-08 15:55U:REGNNews ReleaseThree-Year Results for EYLEA HD(TM) (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
2025-02-04 06:30U:REGNNews ReleaseRegeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion
2025-01-23 12:02U:REGNNews ReleaseAmerica's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
2025-01-21 14:35U:REGNNews ReleaseREGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
2025-01-16 05:45U:REGNNews ReleaseThe Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
2025-01-13 06:30U:REGNNews ReleaseRegeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
2025-01-13 06:16U:REGNNews ReleaseAdjuvant Libtayo(TM) (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
2025-01-13 06:05U:REGNNews ReleaseRegeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
2025-01-07 16:05U:REGNNews ReleaseRegeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025